Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triple Negative Breast Neoplasms × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Stomach Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasm Metastasis 1 Muscle Invasive Bladder Cancer 1 Meningioma 1 Lung Neoplasms 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 DLBCL 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

pembrolizumab 138 Carboplatin 120 Paclitaxel 106 Cyclophosphamide 76 130-nm albumin-bound paclitaxel 58 Capecitabine 55 Gemcitabine 42 Doxorubicin 42 Albumin-Bound Paclitaxel 37 atezolizumab 35 Taxes 34 Cisplatin 31 Nivolumab 30 Docetaxel 28 Epirubicin 27 sacituzumab govitecan 26 Bevacizumab 24 olaparib 23 eribulin 23 Specimen Handling 23 durvalumab 22 camrelizumab 20 Magnetic Resonance Spectroscopy 20 Biopsy 20 Drug Therapy 18 toripalimab 16 liposomal doxorubicin 13 Radiotherapy 13 Everolimus 13 spartalizumab 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡